BioMarin Announces First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioMarin Pharma (BMRN) Tops Q1 EPS by 20c
May 4, 2017 4:06 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 GAAP EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $304 million versus the consensus estimate of $288.98 million.
Non-GAAP income for the first quarter ended March 31, 2017 was $35 million, compared to non-GAAP loss of... More
